Literature DB >> 20308301

Distinct physiologic and inflammatory responses elicited in baboons after challenge with Shiga toxin type 1 or 2 from enterohemorrhagic Escherichia coli.

D J Stearns-Kurosawa1, Valta Collins, Scott Freeman, Vernon L Tesh, Shinichiro Kurosawa.   

Abstract

Shiga toxin-producing Escherichia coli is a principal source of regional outbreaks of bloody diarrhea and hemolytic-uremic syndrome in the United States and worldwide. Primary bacterial virulence factors are Shiga toxin types 1 and 2 (Stx1 and Stx2), and we performed parallel analyses of the pathophysiologies elicited by the toxins in nonhuman primate models to identify shared and unique consequences of the toxemias. After a single intravenous challenge with purified Stx1 or Stx2, baboons (Papio) developed thrombocytopenia, anemia, and acute renal failure with loss of glomerular function, in a dose-dependent manner. Differences in the timing and magnitude of physiologic responses were observed between the toxins. The animals were more sensitive to Stx2, with mortality at lower doses, but Stx2-induced renal injury and mortality were delayed 2 to 3 days compared to those after Stx1 challenge. Multiplex analyses of plasma inflammatory cytokines revealed similarities (macrophage chemoattractant protein 1 [MCP-1] and tumor necrosis factor alpha [TNF-alpha]) and differences (interleukin-6 [IL-6] and granulocyte colony-stimulating factor [G-CSF]) elicited by the toxins with respect to the mediator induced and timing of the responses. Neither toxin induced detectable levels of plasma TNF-alpha. To our knowledge, this is the first time that the in vivo consequences of the toxins have been compared in a parallel and reproducible manner in nonhuman primates, and the data show similarities to patient observations. The availability of experimental nonhuman primate models for Stx toxemias provides a reproducible platform for testing antitoxin compounds and immunotherapeutics with outcome criteria that have clinical meaning.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20308301      PMCID: PMC2876564          DOI: 10.1128/IAI.01435-09

Source DB:  PubMed          Journal:  Infect Immun        ISSN: 0019-9567            Impact factor:   3.441


  47 in total

1.  Membrane cytosolic translocation of verotoxin A1 subunit in target cells.

Authors:  Patricia J Tam; Clifford A Lingwood
Journal:  Microbiology (Reading)       Date:  2007-08       Impact factor: 2.777

2.  Pro-inflammatory cytokine inhibition in the primate using microencapsulated antisense oligomers to NF-kappaB.

Authors:  Carl W Oettinger; Martin J D'souza; Nima Akhavein; Glenn T Peer; Fletcher B Taylor; Gary T Kinasewitz
Journal:  J Microencapsul       Date:  2007-06       Impact factor: 3.142

3.  Sepsis and pathophysiology of anthrax in a nonhuman primate model.

Authors:  Deborah J Stearns-Kurosawa; Florea Lupu; Fletcher B Taylor; Gary Kinasewitz; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2006-08       Impact factor: 4.307

4.  Response to Shiga toxin-1, with and without lipopolysaccharide, in a primate model of hemolytic uremic syndrome.

Authors:  R L Siegler; T J Pysher; R Lou; V L Tesh; F B Taylor
Journal:  Am J Nephrol       Date:  2001 Sep-Oct       Impact factor: 3.754

5.  Circulating granulocyte colony-stimulating factor, C-X-C, and C-C chemokines in children with Escherichia coli O157:H7 associated hemolytic uremic syndrome.

Authors:  François Proulx; Baruch Toledano; Véronique Phan; Marie-José Clermont; Michelle M Mariscalco; Ernest G Seidman
Journal:  Pediatr Res       Date:  2002-12       Impact factor: 3.756

6.  Differential tissue targeting and pathogenesis of verotoxins 1 and 2 in the mouse animal model.

Authors:  Niels W P Rutjes; Beth A Binnington; Charles R Smith; Mark D Maloney; Clifford A Lingwood
Journal:  Kidney Int       Date:  2002-09       Impact factor: 10.612

7.  Chronic sepsis mortality characterized by an individualized inflammatory response.

Authors:  Marcin F Osuchowski; Kathy Welch; Huan Yang; Javed Siddiqui; Daniel G Remick
Journal:  J Immunol       Date:  2007-07-01       Impact factor: 5.422

8.  Associations between virulence factors of Shiga toxin-producing Escherichia coli and disease in humans.

Authors:  P Boerlin; S A McEwen; F Boerlin-Petzold; J B Wilson; R P Johnson; C L Gyles
Journal:  J Clin Microbiol       Date:  1999-03       Impact factor: 5.948

9.  Six at six: interleukin-6 measured 6 h after the initiation of sepsis predicts mortality over 3 days.

Authors:  Daniel G Remick; Gerald R Bolgos; Javed Siddiqui; Jungsoon Shin; Jean A Nemzek
Journal:  Shock       Date:  2002-06       Impact factor: 3.454

10.  Induction of apoptosis of human brain microvascular endothelial cells by shiga toxin 1.

Authors:  Zuhal Ergonul; Alisa K Hughes; Donald E Kohan
Journal:  J Infect Dis       Date:  2002-12-13       Impact factor: 5.226

View more
  33 in total

1.  Baicalin inhibits the lethality of Shiga-like toxin 2 in mice.

Authors:  Jing Dong; Yong Zhang; Yutao Chen; Xiaodi Niu; Yu Zhang; Cheng Yang; Quan Wang; Xuemei Li; Xuming Deng
Journal:  Antimicrob Agents Chemother       Date:  2015-09-08       Impact factor: 5.191

2.  An Escherichia coli O157-specific engineered pyocin prevents and ameliorates infection by E. coli O157:H7 in an animal model of diarrheal disease.

Authors:  Jennifer M Ritchie; Jennifer L Greenwich; Brigid M Davis; Roderick T Bronson; Dana Gebhart; Steven R Williams; David Martin; Dean Scholl; Matthew K Waldor
Journal:  Antimicrob Agents Chemother       Date:  2011-09-26       Impact factor: 5.191

Review 3.  Shiga toxin pathogenesis: kidney complications and renal failure.

Authors:  Tom G Obrig; Diana Karpman
Journal:  Curr Top Microbiol Immunol       Date:  2012       Impact factor: 4.291

Review 4.  Shiga toxins expressed by human pathogenic bacteria induce immune responses in host cells.

Authors:  Moo-Seung Lee; Myung Hee Kim; Vernon L Tesh
Journal:  J Microbiol       Date:  2013-12-19       Impact factor: 3.422

5.  Rescue from lethal Shiga toxin 2-induced renal failure with a cell-permeable peptide.

Authors:  Deborah J Stearns-Kurosawa; Valta Collins; Scott Freeman; Diann Debord; Kiyotaka Nishikawa; Sun-Young Oh; Caitlin S Leibowitz; Shinichiro Kurosawa
Journal:  Pediatr Nephrol       Date:  2011-05-21       Impact factor: 3.714

6.  Shiga toxin subtypes display dramatic differences in potency.

Authors:  Cynthia A Fuller; Christine A Pellino; Michael J Flagler; Jane E Strasser; Alison A Weiss
Journal:  Infect Immun       Date:  2011-01-03       Impact factor: 3.441

7.  Dextran Sulfate Sodium Colitis Facilitates Colonization with Shiga Toxin-Producing Escherichia coli: a Novel Murine Model for the Study of Shiga Toxicosis.

Authors:  Gregory Hall; Shinichiro Kurosawa; D J Stearns-Kurosawa
Journal:  Infect Immun       Date:  2018-10-25       Impact factor: 3.441

8.  Plasma bacterial and mitochondrial DNA distinguish bacterial sepsis from sterile systemic inflammatory response syndrome and quantify inflammatory tissue injury in nonhuman primates.

Authors:  Tolga Sursal; Deborah J Stearns-Kurosawa; Kiyoshi Itagaki; Sun-Young Oh; Shiqin Sun; Shinichiro Kurosawa; Carl J Hauser
Journal:  Shock       Date:  2013-01       Impact factor: 3.454

Review 9.  Advances in the development of enterohemorrhagic Escherichia coli vaccines using murine models of infection.

Authors:  Victor A Garcia-Angulo; Anjana Kalita; Alfredo G Torres
Journal:  Vaccine       Date:  2013-05-22       Impact factor: 3.641

10.  Distinct renal pathology and a chemotactic phenotype after enterohemorrhagic Escherichia coli shiga toxins in non-human primate models of hemolytic uremic syndrome.

Authors:  Deborah J Stearns-Kurosawa; Sun-Young Oh; Rama P Cherla; Moo-Seung Lee; Vernon L Tesh; James Papin; Joel Henderson; Shinichiro Kurosawa
Journal:  Am J Pathol       Date:  2013-02-10       Impact factor: 4.307

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.